ABSI.US Absci Corp

Healthcare Biotechnology USA Stocks
9.14 USD
Close of Nov 13, 2026
2.24 12.55
Market cap
USD 1.57B
P/E
-
P/B
7.03x
ROE
-51.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is ABSI.US undervalued?

Graham number

The Graham number of Absci Corp cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Absci Corp fundamental analysis

No fundamental analysis for Absci Corp yet.

Absci Corp stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Absci Corp

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporat…

Full company profile